Last reviewed 2026-04-19 · How we verify

BAY 987519, SPF 50, P04-147

Bayer · Phase 1 active Small molecule

BAY 987519, SPF 50, P04-147 is a Small molecule drug developed by Bayer. It is currently in Phase 1 development.

At a glance

Generic name	BAY 987519, SPF 50, P04-147
Sponsor	Bayer
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BAY 987519, SPF 50, P04-147 CI brief — competitive landscape report
BAY 987519, SPF 50, P04-147 updates RSS · CI watch RSS
Bayer portfolio CI

Frequently asked questions about BAY 987519, SPF 50, P04-147

What is BAY 987519, SPF 50, P04-147?

BAY 987519, SPF 50, P04-147 is a Small molecule drug developed by Bayer.

Who makes BAY 987519, SPF 50, P04-147?

BAY 987519, SPF 50, P04-147 is developed by Bayer (see full Bayer pipeline at /company/bayer).

What development phase is BAY 987519, SPF 50, P04-147 in?

BAY 987519, SPF 50, P04-147 is in Phase 1.

Manufacturer: Bayer — full pipeline
Compare: BAY 987519, SPF 50, P04-147 vs similar drugs
Pricing: BAY 987519, SPF 50, P04-147 cost, discount & access